Tyvyt (sintilimab)

P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital

Specifically, the patient underwent six cycles of induction therapy with the etoposide plus cisplatin regimen combined with sintilimab, followed by intensity-modulated radiation therapy (pGTV 48 Gy, pCTV 48 Gy), and subsequently received maintenance sintilimab monotherapy. For this highly aggressive SMARCA4-deficient tumor, the sequential treatment strategy of "induction chemotherapy-immunotherapy followed by consolidative radiotherapy" enables long-term disease control, and immunotherapy maintenance also demonstrated significant value in delaying disease progression. The experience from this case could inform the diagnostic and therapeutic approach for this rare subtype of lung cancer.

P2, N=30, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting --> Recruiting

P1, N=16, Recruiting, Sun Yat-sen University

P2, N=23, Not yet recruiting, Sun Yat-sen University

P=N/A, N=1000, Active, not recruiting, Harbin Medical University

Following eight cycles of ifosfamide plus epirubicin chemotherapy, tumor burden was reduced by more than 90%. Although first-line chemotherapy produced marked pulmonary tumor regression, subsequent anlotinib maintenance therapy did not prevent disease progression. In this PD-L1-positive tumor (CPS 10), sintilimab-based combination therapy yielded a marked clinical and radiographic response, supporting further investigation of ICI-based therapy in selected patients with metastatic MPT.

P=N/A, N=715, Completed, Tongji Hospital

P2, N=123, Not yet recruiting, Eastern Hepatobiliary Surgery Hospital

P2, N=32, Recruiting, Nanfang Hospital, Southern Medical University

Patients with resectable stage II-IIIB EGFR (AJCC 8th edition) mutant NSCLC were enroled and received neoadjuvant sintilimab (200 mg) plus carboplatin (area under the curve 5) and nab-paclitaxel (260 mg/m2) for 3 cycles. Patients in stage II cohort received adjuvant osimertinib for up to 2 years while observation for stage I cohort...provided PD-1 regimen (sintilimab), participant compensation and insurance. This work was supported by National Science Foundation of China, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National Natural Science Foundation of China National High-Level Talents Special Support Program, National Natural Science Foundation of China Major Joint Project on Key scientific issues of lung Cancer, Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer, Integrated Project of Major Research Plan of National Natural Science Foundation of China, National Health Commission Medical and Health Technology Development Research Centre Project.

P2, N=90, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting